RESUMEN
Since the linking of mutations in the Cu,Zn superoxide dismutase gene (sod1) to amyotrophic lateral sclerosis (ALS) in 1993, researchers have sought the connection between SOD1 and motor neuron death. Disease-linked mutations tend to destabilize the native dimeric structure of SOD1, and plaques containing misfolded and aggregated SOD1 have been found in the motor neurons of patients with ALS. Despite advances in understanding of ALS disease progression and SOD1 folding and stability, cytotoxic species and mechanisms remain unknown, greatly impeding the search for and design of therapeutic interventions. Here, we definitively link cytotoxicity associated with SOD1 aggregation in ALS to a nonnative trimeric SOD1 species. We develop methodology for the incorporation of low-resolution experimental data into simulations toward the structural modeling of metastable, multidomain aggregation intermediates. We apply this methodology to derive the structure of a SOD1 trimer, which we validate in vitro and in hybridized motor neurons. We show that SOD1 mutants designed to promote trimerization increase cell death. Further, we demonstrate that the cytotoxicity of the designed mutants correlates with trimer stability, providing a direct link between the presence of misfolded oligomers and neuron death. Identification of cytotoxic species is the first and critical step in elucidating the molecular etiology of ALS, and the ability to manipulate formation of these species will provide an avenue for the development of future therapeutic strategies.
Asunto(s)
Esclerosis Amiotrófica Lateral/patología , Neuronas Motoras/patología , Multimerización de Proteína , Superóxido Dismutasa/toxicidad , Animales , Muerte Celular/efectos de los fármacos , Línea Celular , Estabilidad de Enzimas/efectos de los fármacos , Humanos , Modelos Biológicos , Modelos Moleculares , Neuronas Motoras/efectos de los fármacos , Proteínas Mutantes/toxicidad , Mutación/genética , Agregado de Proteínas/efectos de los fármacos , Conformación Proteica , Pliegue de Proteína/efectos de los fármacos , Multimerización de Proteína/efectos de los fármacos , Superóxido Dismutasa/químicaRESUMEN
Brain-derived neurotrophic factor (BDNF) is identified as a potent neuroprotective and neuroregenerative agent for many neurological diseases. Regrettably, its delivery to the brain is hampered by poor serum stability and rapid brain clearance. Here, a novel nanoformulation is reported composed of a bio-compatible polymer, poly(ethylene glycol)-b-poly(L-glutamic acid) (PEG-PLE), that hosts the BDNF molecule in a nanoscale complex, termed here Nano-BDNF. Upon simple mixture, Nano-BDNF spontaneously forms uniform spherical particles with a core-shell structure. Molecular dynamics simulations suggest that binding between BDNF and PEG-PLE is mediated through electrostatic coupling as well as transient hydrogen bonding. The formation of Nano-BDNF complex stabilizes BDNF and protects it from nonspecific binding with common proteins in the body fluid, while allowing it to associate with its receptors. Following intranasal administration, the nanoformulation improves BDNF delivery throughout the brain and displays a more preferable regional distribution pattern than the native protein. Furthermore, intranasally delivered Nano-BDNF results in superior neuroprotective effects in the mouse brain with lipopolysaccharides-induced inflammation, indicating promise for further evaluation of this agent for the therapy of neurologic diseases.
RESUMEN
The purpose of this study was to compare personal exposures to isoflurane from participants' breathing zone samples during animal anesthesia procedures by the method of anesthetic gas delivery and the waste anesthetic gas (WAG) control method utilized. WAG control methods included passive scavenging using charcoal canisters, active scavenging using a building vacuum system, and various local exhaust ventilation systems such as laboratory fume hoods and capture hoods. Methods of anesthesia delivery included induction chambers, face masks (also known as nose cones), and intubation. Personal breathing zone samples were collected using 3M 3520 Organic Vapor Diffusion Monitors and submitted to an International Organization for Standardization (ISO) 17025 accredited laboratory for analysis. When using face masks and induction chambers as the method of anesthesia delivery, local exhaust ventilation systems were found to be the best WAG control method to mitigate personal exposures to isoflurane. Personal exposures to isoflurane were well-controlled when animals were intubated, regardless of whether passive scavenging with an adsorptive charcoal canister or active scavenging with a building vacuum system was used. Personal exposures to isoflurane were highest when induction chambers and face masks were used for anesthesia delivery, and passive scavenging with adsorptive charcoal canisters were used as the control method. This study served to identify best practice WAG control methods for research and veterinary procedures that involve isoflurane anesthesia.
Asunto(s)
Anestesia por Inhalación/veterinaria , Isoflurano/análisis , Exposición Profesional/análisis , Contaminantes Ocupacionales del Aire/análisis , Contaminación del Aire Interior/análisis , Contaminación del Aire Interior/prevención & control , Anestesia por Inhalación/instrumentación , Anestésicos por Inhalación/análisis , Animales , Monitoreo del Ambiente , Depuradores de Gas/veterinaria , Humanos , Exposición Profesional/prevención & control , Ventilación/métodosRESUMEN
Soluble misfolded Cu/Zn superoxide dismutase (SOD1) is implicated in motor neuron death in amyotrophic lateral sclerosis (ALS); however, the relative toxicities of the various non-native species formed by SOD1 as it misfolds and aggregates are unknown. Here, we demonstrate that early stages of SOD1 aggregation involve the formation of soluble oligomers that contain an epitope specific to disease-relevant misfolded SOD1; this epitope, recognized by the C4F6 antibody, has been proposed as a marker of toxic species. Formation of potentially toxic oligomers is likely to be exacerbated by an oxidizing cellular environment, as evidenced by increased oligomerization propensity and C4F6 reactivity when oxidative modification by glutathione is present at Cys-111. These findings suggest that soluble non-native SOD1 oligomers, rather than native-like dimers or monomers, share structural similarity to pathogenic misfolded species found in ALS patients and therefore represent potential cytotoxic agents and therapeutic targets in ALS.
Asunto(s)
Esclerosis Amiotrófica Lateral/enzimología , Biopolímeros/metabolismo , Epítopos/metabolismo , Superóxido Dismutasa/metabolismo , Esclerosis Amiotrófica Lateral/metabolismo , Biopolímeros/química , Cromatografía en Gel , Epítopos/química , Peso Molecular , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Superóxido Dismutasa/químicaAsunto(s)
Linfoma Folicular/radioterapia , Adolescente , Factores de Edad , Biomarcadores , Terapia Combinada , Humanos , Inmunofenotipificación , Linfoma Folicular/diagnóstico , Linfoma Folicular/metabolismo , Masculino , Tomografía Computarizada por Tomografía de Emisión de Positrones , Inducción de Remisión , Resultado del TratamientoRESUMEN
Many therapeutic formulations incorporate poly(ethylene glycol) (PEG) as a stealth component to minimize early clearance. However, PEG is immunogenic and susceptible to accelerated clearance after multiple administrations. Here, we present two novel reformulations of a polyion complex (PIC), originally composed of poly(ethylene glycol)113-b-poly(glutamic acid)50 (PEG-PLE) and brain-derived neurotrophic factor (BDNF), termed Nano-BDNF (Nano-BDNF PEG-PLE). We replace the PEG based block copolymer with two new polymers, poly(sarcosine)127-b-poly(glutamic acid)50 (PSR-PLE) and poly(methyl-2-oxazolines)38-b-poly(oxazolepropanoic acid)27-b-poly(methyl-2-oxazoline)38 (PMeOx-PPaOx-PMeOx), which are driven to association with BDNF via electrostatic interactions and hydrogen bonding to form a PIC. Formulation using a microfluidic mixer yields small and narrowly disperse nanoparticles which associate following similar principles. Additionally, we demonstrate that encapsulation does not inhibit access by the receptor kinase, which affects BDNF's physiologic benefits. Finally, we investigate the formation of nascent nanoparticles through a series of characterization experiments and isothermal titration experiments which show the effects of pH in the context of particle self-assembly. Our findings indicate that thoughtful reformulation of PEG based, therapeutic PICs with non-PEG alternatives can be accomplished without compromising the self-assembly of the PIC.
RESUMEN
Cell-based drug delivery systems have generated an increasing interest in recent years. We previously demonstrated that systemically administered macrophages deliver therapeutics to CNS, including glial cell line-derived neurotrophic factor (GDNF), and produce potent effects in Parkinson's disease (PD) mouse models. Herein, we report fundamental changes in biodistribution and brain bioavailability of macrophage-based formulations upon different routes of administration: intravenous, intraperitoneal, or intrathecal injections. The brain accumulation of adoptively transferred macrophages was evaluated by various imaging methods in transgenic Parkin Q311(X)A mice and compared with those in healthy wild type littermates. Neuroinflammation manifested in PD mice warranted targeting macrophages to the brain for each route of administration. The maximum amount of cell-carriers in the brain, up to 8.1% ID/g, was recorded followed a single intrathecal injection. GDNF-transfected macrophages administered through intrathecal route provided significant increases of GDNF levels in different brain sub-regions, including midbrain, cerebellum, frontal cortex, and pons. No significant offsite toxicity of the cell-based formulations in mouse brain and peripheral organs was observed. Overall, intrathecal injection appeared to be the optimal administration route for genetically modified macrophages, which accomplished targeted gene delivery, and significant expression of reporter and therapeutic genes in the brain.
Asunto(s)
Encefalitis/etiología , Encefalitis/metabolismo , Técnicas de Transferencia de Gen , Macrófagos/metabolismo , Ubiquitina-Proteína Ligasas/genética , Animales , Modelos Animales de Enfermedad , Encefalitis/patología , Expresión Génica , Terapia Genética , Mediciones Luminiscentes , Imagen por Resonancia Magnética , Ratones , Ratones Transgénicos , Imagen Molecular , Tomografía de Emisión de Positrones , Ubiquitina-Proteína Ligasas/metabolismoRESUMEN
An array of carbohydrates masks the HIV-1 surface protein Env, contributing to the evasion of humoral immunity. In most HIV-1 isolates 'glycan holes' occur due to natural sequence variation, potentially revealing the underlying protein surface to the immune system. Here we computationally design epitopes that mimic such surface features (carbohydrate-occluded neutralization epitopes or CONE) of Env through 'epitope transplantation', in which the target region is presented on a carrier protein scaffold with preserved structural properties. Scaffolds displaying the four CONEs are examined for structure and immunogenicity. Crystal structures of two designed proteins reflect the computational models and accurately mimic the native conformations of CONEs. The sera from rabbits immunized with several CONE immunogens display Env binding activity. Our method determines essential structural elements for targets of protective antibodies. The ability to design immunogens with high mimicry to viral proteins also makes possible the exploration of new templates for vaccine development.
Asunto(s)
Vacunas contra el SIDA/inmunología , Anticuerpos Anti-VIH/biosíntesis , Anticuerpos Anti-VIH/inmunología , VIH-1/inmunología , Productos del Gen env del Virus de la Inmunodeficiencia Humana/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Neutralizantes/biosíntesis , Anticuerpos Neutralizantes/inmunología , Fenómenos Biofísicos , Carbohidratos/química , Carbohidratos/inmunología , Cristalografía por Rayos X , Epítopos/química , Epítopos/genética , Epítopos/inmunología , Antígenos VIH/química , Antígenos VIH/genética , Antígenos VIH/inmunología , Humanos , Modelos Moleculares , Conformación Proteica , Ingeniería de Proteínas , Conejos , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Productos del Gen env del Virus de la Inmunodeficiencia Humana/química , Productos del Gen env del Virus de la Inmunodeficiencia Humana/genéticaRESUMEN
Organophosphate poisoning can occur from exposure to agricultural pesticides or chemical weapons. This exposure inhibits acetylcholinesterase resulting in increased acetylcholine levels within the synaptic cleft causing loss of muscle control, seizures, and death. Mitigating the effects of organophosphates in our bodies is critical and yet an unsolved challenge. Here, we present a computational strategy that integrates structure mining and modeling approaches, using which we identify novel candidates capable of interacting with a serine hydrolase probe (with equilibrium binding constants ranging from 4 to 120 µM). One candidate Smu. 1393c catalyzes the hydrolysis of the organophosphate omethoate (kcat/Km of (2.0 ± 1.3) × 10-1 M-1s-1) and paraoxon (kcat/Km of (4.6 ± 0.8) × 103 M-1s-1), V- and G-agent analogs respectively. In addition, Smu. 1393c protects acetylcholinesterase activity from being inhibited by two organophosphate simulants. We demonstrate that the utilized approach is an efficient and highly-extendable framework for the development of prophylactic therapeutics against organophosphate poisoning and other important targets. Our findings further suggest currently unknown molecular evolutionary rules governing natural diversity of the protein universe, which make it capable of recognizing previously unseen ligands.
Asunto(s)
Minería de Datos , Bases de Datos de Proteínas , Organofosfatos/química , Serina Endopeptidasas/química , Hidrólisis , Serina Endopeptidasas/genéticaRESUMEN
The majority of amyotrophic lateral sclerosis (ALS)-related mutations in the enzyme Cu,Zn superoxide dismutase (SOD1), as well as a post-translational modification, glutathionylation, destabilize the protein and lead to a misfolded oligomer that is toxic to motor neurons. The biophysical role of another physiological SOD1 modification, T2-phosphorylation, has remained a mystery. Here, we find that a phosphomimetic mutation, T2D, thermodynamically stabilizes SOD1 even in the context of a strongly SOD1-destabilizing mutation, A4V, one of the most prevalent and aggressive ALS-associated mutations in North America. This stabilization protects against formation of toxic SOD oligomers and positively impacts motor neuron survival in cellular assays. We solve the crystal structure of T2D-SOD1 and explain its stabilization effect using discrete molecular dynamics (DMD) simulations. These findings imply that T2-phosphorylation may be a plausible innate cellular protection response against SOD1-induced cytotoxicity, and stabilizing the SOD1 native conformation might offer us viable pharmaceutical strategies against currently incurable ALS.
Asunto(s)
Esclerosis Amiotrófica Lateral/genética , Mutación , Neuronas/citología , Superóxido Dismutasa-1/química , Superóxido Dismutasa-1/genética , Línea Celular , Supervivencia Celular , Dicroismo Circular , Estabilidad de Enzimas , Humanos , Modelos Moleculares , Simulación de Dinámica Molecular , Fosforilación , Pliegue de Proteína , Procesamiento Proteico-Postraduccional , Estructura Secundaria de Proteína , Superóxido Dismutasa-1/metabolismoRESUMEN
There is a need to monitor the concentration of dissolved oxygen (DO) present in the culture medium for NASA's space cell biology experiments, as well as in earth-based cell cultures. Continuous measurement of DO concentration in the cell culture medium in perfused bioreactors requires that the oxygen sensor provide adequate sensitivity and low toxicity to the cells, as well as maintain calibration over several weeks. Although there are a number of sensors for dissolved oxygen on the market and under development elsewhere, very few meet these stringent conditions. An in-house optical oxygen sensor (HOXY) based on dynamic fluorescent quenching of Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) chloride and a pulsed blue LED light source was developed in our laboratory to address these requirements. The sensing element consisted of the fluorescent dye embedded in a silicone matrix and coated onto a glass capillary. Photobleaching was minimized by a pulsed LED light source. The total noise in the sensor output is 2% and the sensor dynamic range is 0 to 200 mm Hg. The resolution of the sensor is 0.1 mm Hg at 50 mm Hg, and 0.25 mm Hg at 130 mm Hg, while the accuracy is 5%. The LED-based oxygen sensor exhibited stable performance and low drift, making it compatible for space-flight bioreactor systems.